March 23, 2006 – The FDA advisory committee recommended against approving Sparlon, the ADHD drug from Cephalon, admitting the drug was effective, but worrying about its safety; Sanofi-Aventis won an additional indication for Taxotere; GlaxoSmithKline got an expanded indication for an asthma medication; GSK also completed filing a Biologics License Application for FluLaval, a flu vaccine; Pfizer in-licensed a pre-clinical obesity drug candidate from Noxxon Pharma; rumors surfaced that Bayer would make a white-knight bid for Schering; Vertex received funding to move a cystic fibrosis drug into the clinic; Genta will use an oral delivery technology from Emisphere to administer Ganite, an approved inhibitor of bone breakdown; Pharmaxis won approval of an asthma test; and Acadia reported positive data from a Phase II trial of a drug aimed at treatment-induced psychosis that accompanies Parkinson’s disease therapy. The Centient Biotech 200™ gave up 17 points to close at 4004.20, a loss of .42%. More details...
